Montelukast
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea
Conditions
Obstructive Sleep Apnea
Trial Timeline
Jul 1, 2010 → Aug 1, 2014
NCT ID
NCT01027806About Montelukast
Montelukast is a approved stage product being developed by Merck for Obstructive Sleep Apnea. The current trial status is terminated. This product is registered under clinical trial identifier NCT01027806. Target conditions include Obstructive Sleep Apnea.
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Sleep Apnea were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01618929 | Approved | Completed |
| NCT01027806 | Approved | Terminated |
| NCT00492102 | Phase 1 | Completed |
| NCT00559546 | Approved | Completed |
| NCT00721240 | Approved | Completed |
| NCT00148603 | Pre-clinical | Completed |
| NCT00934713 | Approved | Completed |
| NCT00116324 | Phase 3 | Completed |
Competing Products
20 competing products in Obstructive Sleep Apnea